25 Jun

Will David Tepper Be Happy about the AbbVie-Allergan Deal?

WRITTEN BY Anuradha Garg

AbbVie-Allergan deal

On June 25, AbbVie (ABBV) announced that it plans to buy Allergan (AGN) for ~$63 billion. At 10:20 AM ET, Allergan stock rose 27%, while AbbVie stock fell 15%. The transaction entails Allergan shareholders receiving $188.24 in cash and stock for each Allergan share. The transaction implies a premium of 45% over the stock’s closing price on June 24. The deal would reduce AbbVie’s reliance on its blockbuster treatment, Humira, which faces competition from cheaper versions in Europe.

Tepper called for Allergan’s split

Activist investor and Appaloosa Management’s president, David Tepper pressured Allergan to consider selling itself if it couldn’t save its lagging performance. Tepper urged Allergan to separate the roles of chairman and chief executive. Allergan stock has lost ~24% in the last year. The stock underperformed the S&P 500 (SPY), which gained 8.4% during the same period. Drug trial setbacks and competition from generic versions contributed to the stock’s lagging performance.

Will Tepper be happy?

Most of the analysts think that the transaction is a win-win for Allergan shareholders. As reported by CNBC, Cantor Fitzgerald analyst Louise Chen said that the deal is a better-than-expected outcome for Allergan investors and analysts who expected a split. Bloomberg reported that the deal would imply a gain of ~$87 million. Seth Klarman’s Baupost Group could lose ~$100 million. Since Tepper wanted Allergan to sell itself, the deal should be good news. However, we still don’t know if he will be pleased with the transaction price. Bloomberg reported that Appaloosa representatives weren’t available to comment.

Latest articles

Even as Disney+ launch pulled on NFLX stock, Netflix leadership believes the company will survive the attack on its market dominance.

Fake bitcoin investment ads put Facebook in trouble with Dutch billionaire and Big Brother reality show founder John de Mol.

On Wednesday, Barclays initiated coverage on Ralph Lauren (RL) stock with an “overweight” rating. Barclays put a target price of $130 on the stock.

During the Golden Steering Wheel awards ceremony, Tesla’s (TSLA) CEO Elon Musk revealed that Berlin was selected for the company's next Gigafactory.

Last month, it looked like phase one of a US-China trade agreement was a done deal. However, several obstacles have appeared.

The strong sell-off continues in Energy Transfer (ET) stock. The stock lost another 4% and closed at its three-year low of $11.16 on Wednesday.